论文部分内容阅读
目的探讨低分子肝素与血栓通冻干粉针联合用药治疗非ST段抬高急性冠脉综合征的临床效果。方法将80例非ST段抬高急性冠脉综合征病人随机分成常规治疗的对照组及治疗组,治疗组在常规治疗的基础上加用低分子肝素5000 IU皮下注射,每12小时1次,血栓通冻干粉针450 mg每日静脉滴注,连续治疗2周。观察两组病人心绞痛缓解、缺血性心电图改善及复合终点事件的发生率(死亡+急性心肌梗死例数)。结果治疗组心绞痛缓解、缺血性心电图改善总有效率分为80%和77.7%,复合终点事件的发生率为8.89%;对照组心绞痛缓解、缺血性心电图改善总有效率分别为60%和40%,复合终点事件的发生率为20%。两组结果比较差异有统计学意义(P<0.01)。结论低分子肝素(LMWH)联合血栓通冻干粉针治疗非ST段抬高急性冠脉综合征病人疗效好,副作用少,安全有效。
Objective To investigate the clinical effect of low molecular weight heparin combined with Xueshuantong freeze-dried powder injection in the treatment of non-ST segment elevation acute coronary syndrome. Methods Eighty patients with non-ST segment elevation acute coronary syndrome were randomly divided into routine treatment control group and treatment group. The treatment group was given subcutaneous injection of low molecular weight heparin 5000 IU subcutaneously once every 12 hours on the basis of routine treatment, Thrombosis freeze-dried powder 450 mg daily intravenous infusion, continuous treatment for 2 weeks. Angina pectoris relief, ischemic electrocardiogram improvement and composite end point incidence (death + acute myocardial infarction) were observed. Results The angina pectoris was relieved in the treatment group. The total effective rate of the improvement of ischemic electrocardiogram was 80% and 77.7% in the treatment group, and the incidence of the composite end point was 8.89%. In the control group, the angina pectoris was relieved and the total effective rate of the ischemic electrocardiogram was 60% 40%, and the composite end point was 20%. The difference between the two groups was statistically significant (P <0.01). Conclusion Low molecular weight heparin (LMWH) combined with Xueshuantong freeze-dried powder injection is effective and safe in patients with non-ST elevation acute coronary syndrome.